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Purpose: Novel irradiation techniques are continuously introduced in radiotherapy to optimize the accuracy, the
security and the clinical outcome of treatments. These changes could raise the question of discontinuity in
dosimetric presentation and the subsequent need for practice adjustments in case of significant modifications. This
study proposes a comprehensive approach to compare different techniques and tests whether their respective
dose calculation algorithms give rise to statistically significant differences in the treatment doses for the patient.
Methods: Statistical investigation principles are presented in the framework of a clinical example based on 62 fields of
radiotherapy for lung cancer. The delivered doses in monitor units were calculated using three different dose
calculation methods: the reference method accounts the dose without tissues density corrections using Pencil Beam
Convolution (PBC) algorithm, whereas new methods calculate the dose with tissues density correction for 1D and 3D
using Modified Batho (MB) method and Equivalent Tissue air ratio (ETAR) method, respectively. The normality of the
data and the homogeneity of variance between groups were tested using Shapiro-Wilks and Levene test, respectively,
then non-parametric statistical tests were performed. Specifically, the dose means estimated by the different calculation
methods were compared using Friedman’s test and Wilcoxon signed-rank test. In addition, the correlation between the
doses calculated by the three methods was assessed using Spearman’s rank and Kendall’s rank tests.
Results: The Friedman’s test showed a significant effect on the calculation method for the delivered dose of lung
cancer patients (p <0.001). The density correction methods yielded to lower doses as compared to PBC by on average
(−5 ± 4.4 SD) for MB and (−4.7 ± 5 SD) for ETAR. Post-hoc Wilcoxon signed-rank test of paired comparisons indicated
that the delivered dose was significantly reduced using density-corrected methods as compared to the reference
method. Spearman’s and Kendall’s rank tests indicated a positive correlation between the doses calculated with the
different methods.
Conclusion: This paper illustrates and justifies the use of statistical tests and graphical representations for dosimetric
comparisons in radiotherapy. The statistical analysis shows the significance of dose differences resulting from two or
more techniques in radiotherapy.
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Radiotherapy techniques
The main challenge in radiation therapy for cancer treat-
ment is to obtain the highest probability of tumor control
or cure with the least amount of morbidity and toxicity to
normal surrounding tissues (organs at risk). Currently, nu-
merous different machines and several techniques are* Correspondence: abdulhamedc@yahoo.com
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unless otherwise stated.used to irradiate the tumors, as three–dimensional ra-
diation therapy (3D-RT), intensity-modulated radiation
therapy (IMRT), tomotherapy, particle therapy and
volumetric-modulated arc therapy (VMAT). The expected
clinical results of radiotherapy are related to the calculated
dose. The advance in technology provides successive gen-
erations of Treatment Planning Systems (TPS) for radio-
therapy which include new dose calculation algorithms
and allow new irradiation techniques. These algorithms
compute the dose for a given technique, subsequently
showing the results as dosimetric parameters and display-
ing dose volume histograms or spatial isodoses. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Data collection table for statistical analysis
Patients Reference Tested method 1 Tested method 2
1 Dr,1 D1,1 D2,1
2 Dr,2 D1,2 D2,2
n Dr,n D1,n D2,n
μr ± SDr μ1 ± SD1 μ2 ± SD2
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on the assessment of these TPS output. When a new tech-
nique or a new algorithm is implemented, the calculated
and distributed doses can differ from those computed by
algorithms that constitute the current standard and refer-
ence. It is very easy to compare the spatial dose distribu-
tion of two DICOM RT files (the file produced by the
reference method and the file produced by the new
method) by using γ index or χ index [1,2]. Any difference
between the computed dose will be visualized using γ or χ
maps [3]. If ignored, this alteration could endanger the
clinical outcome of the treatment. In particular, the het-
erogeneity correction introduces an under dosage to the
target when the latter is imbedded in low density tissues,
as in thoracic situation. Therefore, prescription habits
should be adapted to the new calculation methods and
strong connection between dosimetric methods and pre-
scription understanding should be established to avoid
dosimetric improvement to turn into clinical regression
[4]. Currently, algorithms and irradiation techniques are
both able to modify independently the dosimetric outcome.
Although the medical physicists validate any treatment
plan according to the international recommendations for
radiotherapy, these alterations are supposed to have con-
sequences on the clinical outcome [5,6]. One should pro-
vide the radiation oncologist with a tool allowing him to
assess the reality and the extent of these modifications, to
help him integrate them into his everyday practice. Ideally,
the assessment should be possible using small data sets of
patients. That way, each department could perform the as-
sessment tests without investing too much time and re-
sources. At this extend, radiotherapy offers the valuable
situation in which each patient case could be recalculated
in many different ways easily providing paired series of
data. This paper presents a series of statistical tests imple-
mented in a step by step procedure that should help the
radiation oncologist comparing the dosimetric outcome of
different dose calculation algorithms. The procedure is
presented using a concrete example and putting the em-
phasis on the application in radiotherapy rather than the
underlying mathematical principles, which are not de-
tailed. Each section gives a brief description of the aim
and the condition of use of the statistical tests. The goal is
to provide the radiation oncologist and the physicists in-
terpretable results to help them to validate new dose cal-
culation methods.
The need of statistical analysis in radiotherapy
When comparing algorithms or techniques, the statis-
tical analysis has to answer the key question: are there
real differences between two or more calculated dose
distributions? By principle, the main objective of any
progress in radiotherapy is to improve the clinical out-
come by increasing the dose to the tumor and reducingthe dose to the organs at risk. The dosimetric progress,
by the improvement of the accuracy of the calculation, is
supposed to contribute to this goal. Statistical tests are
used to make probability-based decisions regarding dif-
ferences measured between different conditions, e.g., dif-
ferent radiation techniques. For example, are there real
dosimetric differences, assessed by the physicist, which
could be anticipated by the radiation oncologist as a real
benefit or a possible risk for the patient outcome using
RT-3D or IMRT techniques.
To compare different techniques or dose calculation
algorithms, all dosimetric data are calculated with a
unique set of images for a given patient, whatever the
number of different algorithms to compare. This pro-
vides the radiotherapist with paired data that can be ana-
lyzed using statistical tests for repeated measures, e.g.,
paired t-test when only comparing two techniques or
ANOVA when comparing more than two techniques.
All statistical tests used in this study were performed
with the R programming language [7,8].Methods
Data collection
The first step consists in preparing and arranging data
for further analysis. In order to evaluate the treatment
plan for radiotherapy, several dosimetric parameters can
be considered:
 Delivered dose in monitor unit.
 Spatial distribution of dose: for example the isodose
curves 100% and 95% inside the PTVs can be
compared.
 Volumetric distribution: the use of dose volume
histogram allows comparing the maximum dose,
minimum dose, mean dose, etc.
 Quality index: to compare the conformity plan, the
dose homogeneity in PTV and the protection of
organs at risk.
Using 3 techniques, one will therefore have 3 values
for each dosimetric parameter. In this study, one refer-
ence method was compared with 2 new tested methods.
Specifically, the reference dose (Dr,1) was compared to
(D1,1), and (D2,1). Table 1 presents the data from patients
with a sample size “n” using 3 techniques for radiation
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are presented for each technique (μ ± SD).
For each parameter, data can then be split into two
groups: reference data and calculated data resulting from
the novel methods. A first simple and very straightfor-
ward step consists in assessing whether the dose that
would be delivered using the novel method(s) is higher
or lower than the one that would be delivered using the
reference method. The difference in percent between the
novel and reference methods can be calculated as:
ΔDose %ð Þ ¼ Dtested−Dreferenceð Þ  100=Dreference ð1Þ
A positive value means that the dosescalculated by the
tested method are higher than the doses calculated by
the reference method (Dtested > Dreference). A negative value
would mean the opposite (Dtested < Dreference).
For the radiation oncologist to be able to reach the
best medical decision it would be valuable to know or be
able to estimate how many cases or beams are required
to detect potential differences between methods. One
way to estimate the number of cases or beams which
would be necessary to be able to observe a significant
difference between two methods consists in using a
power test. For this purpose, the following equation can
be used:
n ¼ Zαð Þ2SD 1−SDð Þ = confidence levelð Þ2 ð2Þ
Assuming that α = 5% the Zα = 1.96 shows the critical
value for 95% confidence level for normal distribution.
To determine the sample size, one should beforehand,
set the significance level (α) and the statistical power of
the test to come. α defines the probability of “errone-
ously” concluding that the observed difference between
means reflects a real difference between methods when
this difference between means was actually observed by
chance. α is typically set to 0.05 (p-value) which corre-
sponds to a 5% chance to conclude to a significant dif-
ference when there is no actual difference. Statistical
power corresponds to the probability of detecting an ac-
tual difference. Applied to the comparison of radiother-
apy methods, statistical power therefore corresponds to
the probability of “correctly” concluding that the ob-
served difference between means reflects a real differ-
ence between methods. A conventional choice of power
is either 80% or 90% [9,10]. Power is usually calculated
before data collection in order to estimate the required
sample size. In some case, statistical power is calculated
after data collection to verify whether the non-significance
of the result might be due to a lack of power, but this prac-
tice is usually discouraged [11]. Here we calculated statis-
tical power after data collection for illustrative purposes.
For that, we used PS software, which provides estimates ofpower and sample size, and allowed us to plot sample size
versus power for a specified alternative hypothesis [12].
In addition to this power calculation, we used boot-
strapping to estimate the minimum number of patients
or cases that we would have needed to observe a signifi-
cant difference between methods or groups with our
data. We chose this a posteriori approach because we
already had data collected for 62 beams. It also allowed
us to compare the results with the estimation provided
by the power analysis.
As an additional note, we would like to mention that
P-values do not really measure the importance of the ef-
fect. Therefore, statistical tests can be complemented by
an assessment of the effect size (effsize). We choose to
use “Pearson’s r”, to measure and estimate the amount
of total variance in the data resulting from the difference
between the compared groups.
Comparing methods
Several statistical tests can be used to compare means.
These tests can be classified in two categories: paramet-
ric and non-parametric tests. Parametric tests make as-
sumptions about the type and distribution of the data. If
the data fulfill the assumptions of parametric data, para-
metric tests can be used. If the data do not fulfill these
assumptions, non-parametric tests must be used. Non-
parametric tests make fewer assumptions about the type
and distribution of the data.
Checking assumptions of parametric data
Before choosing a method to compare means, two main
assumptions regarding data distribution must be assessed.
Specifically, one should test whether: data are normally
distributed and the variances of the samples to be com-
pared are similar (homogeneity of variance). Several statis-
tical tests can be used to assess whether data are normally
distributed or not (see [13] for an overview). Among
those, the test that is the most widely used is the Shapiro-
Wilks test, notably because it is more powerful than most
other normality tests [14], i.e., it provides higher probabil-
ity of detecting actual departure from normality in the
data (statistical power is addressed above). The Shapiro-
Wilks test estimates the probability that any given sample
is drawn from a normal population. It can be complemen-
ted by computing the skewness and the kurtosis of the
sample distribution. The skewness relates to the symmetry
of the distribution (as shown in Figure 1). A skewed distri-
bution is not symmetrical as the most frequent scores are
clustered at one end of the scale. Kurtosis gives the degree
to which scores cluster at the end of the distribution. A
normal distribution has both a skewness and an excess
kurtosis of 0. To assess whether the skewness and kurtosis
of a sample deviate significantly from those of a normal
distribution, one can divide the calculated skewness and
Figure 1 Density plots showing the deviation of normality and the positive skewness (i.e., clustering at the lower end (left) of the scale).
Negative skewness would have shown clustering at the higher end of the scale. A normal curve using the mean and standard deviation of the data as
parameters has been drawn on top of the histograms to show the deviation of normality.
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values greater than 1.96 indicates a significant deviation.
These statistical tests should always be complemented by
a visual inspection of the data.
Density distribution histograms are very useful for
assessing normality. This type of representation displays
the density distribution of the scores. In other words, it
provides visual information about the shape of the distri-
bution. In the ideal case, the data should be distributed
symmetrically around the center of all scores. The data
distribution can deviate from normal distribution if there
is a lack of symmetry (skewness). Skewed distributions
are not symmetrical and, instead, the most frequent
scores (the tall bars on the graph) are clustered at one
end of the scale. So, the typical pattern is a cluster of fre-
quent scores at one end of the scale and the frequency
of scores tailing off towards the other end of the scale. A
skewed distribution can be either positive or negative ac-
cording to the shape of the asymmetry.
To assess whether the assumption of homogeneity of
variance is fulfilled, the most commonly used test is the
Levene’s test. However, the Brown-Forsythe test consti-
tutes a more robust (and often preferable) alternative.
These tests estimate whether the variance is similar/
comparable in the different samples by analyzing devia-
tions from the mean (Levene) or the median (Brown-
Forsythe) of the distribution. Applied to our radiotherapy
example, these tests can be used to assess whether the
variance of the dosimetric values calculated by the differ-
ent techniques is similar. One should mention that testing
for homogeneity of variance is not necessary with repeated
measures design, i.e., designs in which the same subjects
are tested on the different conditions (as it is the case
here). However, we mention it in the analysis for the sake
of the example. Box and whisker diagram boxplot is a type
of visual representation that completes the Levene’s orBrown-Forsythe test when evaluating the homogeneity of
variance between groups. Boxplots provide important in-
formation about the distribution and variability of the
data. They display the minimum and maximum values of
the distribution as well as the 25th percentile, 50th per-
centile (median) and 75th percentile. Figures 2 and 3 show
the statistical methods which could be used for radiother-
apy depending on whether data are parametric or not.
Comparison of techniques
To compare two techniques (i.e., two means) when mea-
sures are repeated, paired Student parametric test or
Wilcoxon signed-rank non-parametric test can be used,
as shown in Figures 2 and 3. With independent mea-
sures (i.e., independent samples), independent Student
t-test and Mann Whitney test for non-parametric data
are usually used.
To compare more than two techniques, a two-step
analysis should be conducted. The first step consists in
conducting an omnibus test to assess whether there is
an overall effect of technique, i.e., whether all techniques
are the same or not. If the data fill the assumptions of
parametric data (normally distributed data and homo-
geneity of variance between groups), this omnibus test
can be performed using a one-way Analysis of Variance
(ANOVA) for repeated measures, with correction for
violation of sphericity if needed [15]. To compare the
outcome of different techniques for more than one dosi-
metric parameter, one can use a multivariate analysis of
variance (MANOVA), but this point will not be dis-
cussed here. If the data do not fill the assumptions of
parametric data, the omnibus test must be performed
using a non-parametric equivalent of the repeated mea-
sures ANOVA, namely Friedman’s repeated measures
test (the Kruskal-Wallis test can be used for independent
measures). Once this omnibus test has been performed,
Figure 2 Flowchart of statistical methods for parametric data.
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consists in conducting multiple paired-t-tests (multiple
comparisons) to compare techniques in a two by two
fashion. With parametric data, these comparisons can be
performed using multiple paired t-tests (see above).
With non-parametric data, multiple Wilcoxon signed-
rank tests can be used. For both parametric and non-
parametric multiple comparisons, the significance level
must be corrected in order to avoid inflating type-1
error probability, i.e., the probability of detecting a sig-
nificant difference when actually there is not any (i.e.,
false positive). One way of doing that is to divide the sig-
nificance threshold by the total number of paired
comparisons performed (e.g., with three comparisons,
alpha = 0.05/3 = 0.0166). This correction method is
known as Bonferroni correction. Bonferroni correction
is the most conservative correction method. Specifically,
it controls strictly the probability of false positive, but
this is at the cost of reducing the statistical power of the
test, i.e., the ability to detect an actual difference. WhenFigure 3 Flowchart of statistical methods for non-parametric data.power is an issue, less conservative correction methods
can be used, as for instance the Holm method, in which
the correction factor applied depends not only on the
number of comparisons performed but also on the rank of
the p values. Finally, several other post-hoc procedures are
available to compare several means, as Tukey’s honest sig-
nificant difference test (HSD), Newman-Keuls test, or
Fisher’s least significant difference (LSD) test, to cite a few.
Tukey’s HSD is one of the most widely used, especially
when the number of means to compare is relatively large,
as it offers good control over false positives while keeping
decent power (see [16] for a specific comparison between
post-hoc procedures).
Correlation between techniques
To measure the strength of the relationship between
two techniques (i.e., estimate how much two techniques
are related), for parametric data, Pearson correlation co-
efficient can be used. For non-parametric data, one
should rather use Spearman’s ‘rho’ correlation coefficient
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assumptions of parametric data. Therefore, Spearman’s
rank correlation and Kendall’s rank were used.
Medical decision
A p-value (p ≥ 0.05) implies that the differences observed
between means probably occurred by chance (rather
than reflecting a real difference between the methods).
In this case, we can assume that there is not enough evi-
dence to conclude that the new technique gives rise to
significant dosimetric difference with respect to the ref-
erence technique. Conversely, a p < 0.05 implies that the
differences observed probably reflect existing differences
between the methods. In this case, we could expect a
significant dosimetric difference and therefore some
medical impact.
Clinical tests for radiotherapy
The following analyses of data from radiotherapy present
an overview of how statistical methods may be used for
the evaluation of real treatment plans. In this study, a
very common improvement of dose calculation was used
as an example of a software change producing a true
situation of decision in radiotherapy. The statically
methods described in this study have been applied to
lung cancer using 62 treatment fields with 18MV photon
beams. Table 2 shows the site locations, the prescribed
dose and the treatment fields for all patients.
The aim was to compare the delivered dose in monitor
units resulting from three dose calculation methods
keeping exactly the same beam setting. Calculations dose
were performed, for the present demonstration, using
the Pencil Beam Convolution (PBC) algorithm integrated
in TPS Eclipse® (Varian, version 8.1). PBC algorithm in-
cludes two calculation modes: without heterogeneity cor-
rection using (PBC) and with heterogeneity correction
using the Modified Batho (MB) method and Equivalent
Tissue air ratio (ETAR) method. Heterogeneity corrections
are always based on relative electron densities obtained
from a CT-scan [17,18].
Reference method: calculates the dose without taking
into account the tissues densities using PBC.Table 2 Characteristics of the patients treated with 3D
radiotherapy using 18MV, location tumour, dose
prescription and treatment fields
Patients Locations Dose (Gy) Fields
1 Lung parenchyma 66 6
2 Left retro cardiac 66 17
3 Top left lung 70 10
4 Mediastina 60 9
5 Mediastina 60 12
6 Oesophagus 55 8MB method: this method is based on the Tissue
Maximum Ratio (TMR) and calculates the density distri-
bution in 1D. The correction factor is given by:
CF ¼ μen =ρð ÞN= μen=ρð Þw
YN
m¼1
TMR z−zm þ zbuð Þð Þ μm−μm−1ð Þ=μw
ð3Þ
Where μm and μw are the linear attenuation coeffi-
cients of the material in layer (m) and water (w) respect-
ively; Zbu is the build-up depth and Zm is the distance
along the beam from the surface to the layer (m) in the
phantom. μen/ρ is the mass energy absorption coefficient
of the material in layer (N).
ETAR method: calculates the dose taking into account
3D tissues densities correction. It uses the Tissue Air
Ratio (TAR) dependent on the effective beam radius (~r )
to take account of scattered radiation and effective depth
(d′) for primary beam correction. The correction factor
is given by:
CF ¼ TAR d′; ~rð Þ
TAR d; rð Þ ð4Þ
Where d′; ~r are the effective values of depth (d) and
beam radius (r) respectively.
The statistical analyses in this study were performed to
assess whether using new method MB or ETAR rather
than the reference method (PBC) would give rise to a
significant reduction or increase in the delivered dose.
The analyses were carried out using the R environment
for statistical computing and visualization. All data were
imported in R from Excel®.
Results
Assessment of the assumptions of parametric data
Normality
Figure 1 shows the density distribution of the dosimetric
values calculated by the three methods. A clear deviation
from normality and positive skewness (i.e., clustering at
the lower end (left) of the scale) can be observed. Table 3
presents the results of the Shapiro-Wilk test, as well as
skewness and kurtosis values (divided by their standard
error) for the reference and two new methods. The
Shapiro-Wilk test shows a significant deviation from the
normality (confirming what can be visually observed in
Figure 1). We note also a significant positive skewness
and significant kurtosis p < 0.05.
Homogeneity of variance
Figure 4 shows the boxplot for all three methods indicat-
ing 62 fields. Because we are dealing here with repeated
measures, running a Levene’s or Brown-Forsythe test is
not necessary. We ran nonetheless a Brown-Forsythe
Table 3 Observed results from Shapiro-Wilks test, skewness
and excess kurtosis for the reference and two new methods
Tests Results Reference Method 1 Method 2
Shapiro-Wilks W 0.80 0.81 0.81








p -value < 0.001 < 0.001 < 0.001
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different groups have significantly different variances,
F(2,183) = 0.987 and p < 0.05, even if this difference is not
striking when examining boxplot representations of the
three distributions (Figure 4).
All diagnostic tests indicate that the data do not fulfill
the assumptions of parametric data. Accordingly, statis-
tical tests were conducted using non-parametric methods.
As presented in the Figure 3, means were compared using
the Friedman rank and Wilcoxon signed-rank tests.
Comparisons of dose calculation methods
Figure 5 shows the number of beam distributions re-
garding the dose differences (in percent) between the
reference method and new methods 1 and 2. The density
correction methods yielded to lower doses as compared
to PBC by on average (−5 ± 4.4SD) for MB and (−4.7 ± 5SD)
for ETAR. Considering these results, the use of MB or
ETAR instead of PBC to treat the patients would result in
under dosage in the PTVs. This difference may have a
clinical impact compared to the reference plan.Figure 4 Boxplot indicating the minimum and maximum
values, the 25th percentile, 50th percentile (median) and
75th percentile.Therefore, one should assess whether this difference is
significant or rather occurred by chance. Friedman rank
sum test showed a significant overall effect of tech-
nique,χ2(2) = 53.45, p < 0.001.
MB and ETAR methods were then individually com-
pared to PBC using Wilcoxon signed-rank tests. The
tests showed that both methods gave rise to doses that
were significantly different from the PBC, sum all posi-
tive and negative ranks VWilcoxon =1207 and 1216 for
MB vs PBC, and ETAR vs PBC, respectively, with
p < 0.001 in both cases. The “Pearson’s r” test showed eff-
size = −0.53 and −0.50, for MB vs PBC and ETAR vs PBC,
respectively. On the other hand, MB and ETAR did not
differ from one another, Vwilcoxon = 121.5 with p = 0.31
(which is far above the corrected “p” for multiple paired-
comparisons = 0.05/3 = 0.016) and effsize = −0.19. Figure 6
presents the mean dose that would be delivered using
PBC, MB and ETAR. For each method, error bars indicate
the 95% confidence interval adjusted for repeated-measures
according to Loftus et al. [19].
As reported above, with 62 beams, we observed signifi-
cant differences between MB and PBC as well as be-
tween ETAR and PBC. In order to determine how many
subjects or beams would have been necessary to observe
significant differences between our methods (i.e., MB vs
PBC and ETAR vs PBC), we used a bootstrap procedure.
This consisted in taking 1000 random samples of size
“n” (with n going from 5 to 62) for each of the two
methods MB and ETAR we wanted to compare. For
each sample, p-value was computed using Wilcoxon
signed-rank test. For every “n” the mean p-value across
the 1000 random samples was computed. Figure 7 shows
the computed mean p-values for each sample size (from
5 to 62 beams). As shown in the left panel, 8 beams
would have been sufficient to observe a significant differ-
ence between MB and PBC, whereas observing a signifi-
cant difference between ETAR and PBC would have
required 10 beams (right panel).
Figure 8 shows the statistical power as a function of
sample size using Wilcoxon signed-rank test. It can be
seen from Figure 8 that to achieve 80% power it requires
about 8 and 10 treatment fields to compare PBC with
MB and ETAR, respectively. These estimations corres-
pond well to the numbers provided by the bootstrap
procedure reported above. We can also note that the use
of 62 treatment fields in this study leads a very high
power.
Relationship between dose calculation methods using
correlation and regression
Figure 9 shows the correlation plots between the refer-
ence and the new methods. It can be seen in Figure 9
that there was a strong correlation between PBC with
MB and ETAR. Specifically, for MB, Kendall’s rank ‘tau’
Figure 5 Frequency distribution of dose differences between PBC with MB (left) and ETAR (right). For the majority of beams, the
calculated dose is lower with MB and ETAR than with PBC.
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ping) [0.91; 0.97]) with p < 0.001, and Spearman’s rank
‘rho’ was 0.99 (95% BCa [0.99; 1.0]) with p < 0.001. For
ETAR, Kendall’s rank ‘tau’ was 0.94 (95% BCa [0.90,
0.96]) with p < 0.001, and Spearman’s rank ‘rho’ was 0.99
(95% BCa [0.98, 1.0]) with p < 0.001.
The 95% BCa for the slope was [0.90 ; 0.96] and [0.92;
0.97] for the comparison between PBC with MB and
ETAR respectively. The 95% BCa for the intercept was
[−0.83 ; 3.67] and [−1.14 ; 2.95] for the comparison be-
tween PBC with MB and ETAR respectively. In both
cases, the coefficient of determination was very high (R2 =
0.996) with p < 0.001. The 95% confidence bootstrapFigure 6 The bars show the mean dose that would be delivered using
interval adjusted for repeated-measures.percentile (95% BCa) interval for correlation and regres-
sion has been computed using non-parametric bootstrap-
ping with 2000 replicates.
Medical decision
The mean comparison tests between the PBC method
with MB or ETAR indicated significant differences in
dose calculation (p < 0.001). In other words, the ob-
served differences probably reflect existing differences
between the methods. In addition, the bootstrapping
procedure indicated that significant differences between
the reference and the new methods could be observed
with as little as 8 and 10 beams, respectively. Therefore,the different methods. Error bars indicate the 95% confidence
Figure 7 p-values estimated by bootstrap procedure, indicating the average p-value for each sample-sizes going from 5 to 62. The left
panel corresponds to the comparison between MB and PBC, and right panel to the comparison between ETAR and PBC. The red dashed line
corresponds to a significance threshold of 0.05 and the blue dashed line to an adjusted significance threshold of 0.025 (0.05/2 to correct for
two comparisons).
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very likely bear a clinical impact.
The regression analyses show slopes of 0.94 and 0.95
for MB and ETAR, respectively (see Figure 9). The slope
represents the change associated with the MB and ETAR
compared to PBC. Should these methods be equivalent,
these values for slope would have been equal to one. In
this study, the slope values are below 1, with 95% confi-
dence intervals of [0.90; 0.96] and [0.92; 0.97], respect-
ively. These slope values confirm the average difference
of 5% and 4.7% computed with equation 1 for MB and
ETAR. This overall difference is the main result of this
study, and confirms that the prescribed dose should be
adjusted by on average +5% and +4.7% using MB and
ETAR, respectively.
However, different cancer sites should be considered
individually before making any general rule of dose
modification. We recommend presenting the complete set
of statistical information including mean, SD, confidenceFigure 8 Statistical power as a function of sample size using Wilcoxointervals, p-value, sample size and graphical data analysis
to the medical staff. These information will help the
radiation-oncologists to take a decision about the modifi-
cation of the irradiation technique and dose prescription.
The confidence interval, which is routinely computed by
all statistical packages, shows the size of difference which
could be observed. The width of a confidence interval de-
pends on the mean and standard deviation of the results.
Discussion
Among the numerous statistical methods available, the
medical physicist has to make a choice well adapted to
the particularities of radiation therapy. At first, the par-
ticular nature of the data and the way they are produced
need a deep analysis of their quality. In particular, one
should assess whether the data at hand fulfill the as-
sumptions of parametric data, i.e., are distributed nor-
mally and have similar variance between groups. When
the data fulfill these assumptions, Student t-test or onen test.
Figure 9 Correlation between PBC with MB (left) and ETAR (right). The line is computed using a least square regression method, and is
defined by its slope b1 and intercept b0 as: Yi = b0 + b1Xi, where Yi is the outcome, Xi is the i
th participant’s score of the predictor variable.
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data do not fulfill these assumptions, alternative non-
parametric tests should be used, as for instance the
Wilcoxon signed-rank test or Friedman ANOVA (when
dealing with repeated measures). The non-parametric
Wilcoxon rank test takes into account the signed-rank of
the difference between each pair of measures instead of
using all the absolute data. It does not require a normal
distribution and does not considers the size of the differ-
ence. These features make the Wilcoxon signed-rank test
particularly fit for radiotherapy data analysis, since these
data are “naturally” paired according to the possibility to
generate multiple different results with each medical case.
In case of simultaneous comparison of multiple parame-
ters (i.e., not only the delivered doses per monitor unit but
also volumetric distribution, etc.), multivariate ANOVA
can be performed (not used in this paper). However, an
in-depth discussion between medical physicists and statis-
ticians is strongly encouraged in order to determine which
tests and analyses are the most appropriate for the data at
hand (e.g., use of parametric vs non-parametric tests).
We compared one parameter using three methods for
calculation dose. The example given in this study con-
cerning the delivered dose using 1D or 3D dose calcula-
tion is an exemplary problem in radiotherapy. The
clinical effect in radiotherapy depends on the delivered
dose, a small difference in delivered dose being worth to
be considered since it could affect the clinical results.
Concerning the delivered dose, we observed a significant
difference between reference method and both tested
methods (p < 0.05). However, p-value gives little infor-
mation about the results, for example, using 5% level for
alpha error, the p-value shows only if the difference be-
tween the two techniques has a statistical significance or
not. It does not give the size of the difference between
two techniques. This information can be gathered com-
puting the percentage of difference between two tech-
niques (as we did here) but also computing the effectsize (here the Pearson’s r) which is a standardized meas-
ure (always between −1 and 1) of the importance of the
observed effect. In our study, the measured effect sizes
were quite large (above 0.5 in absolute value) for both
comparisons of the new methods with the reference
method.
The calculation of sample size is crucial in any clinical
study. It depends on the significance level, the wished
power, as well as the expected effect size and SD. The
sample size for clinical and statistical studies is the main
difficulty for radiotherapy. For practical reasons, it would
be welcome to use only few patients for realizing the
statistical analysis, and then to generalize the results to a
large population. In radiotherapy it is rare to use a large
number of patients in order to validate the novel irradi-
ation technique at the level of a common department.
Most of the studies in radiotherapy are including be-
tween 10 and a few hundred patients. Most of the time,
a novel technique is quickly integrated in a radiotherapy
department and the physicists has not enough time to
test a large sample of patient. In this case, the radiation-
oncologist and the physicists will have to realize the stat-
istical analysis using a small sample size, which is actu-
ally possible providing one uses cautiously the proper
methods. As mentioned above, one possibility to esti-
mate the required sample size for an expected effect size
is to use a power analysis. Because we already had data
collected (62 beams), we chose to rather use a bootstrap
approach to estimate the minimum number of patients
or cases that we would have needed to observe a signifi-
cance difference between methods or groups. We have
seen that a significant difference between our methods
could be observed with relatively small sample, namely
eight and ten beams.
Interestingly enough, this approach is basically funded
on the analysis of differences and in particular dose dis-
tribution differences. Therefore it can be adapted to
compare any type of situation resulting at last in
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different machines, even assessing the identity of mirror
machines, and so on.
Conclusion
We illustrate in this study the use of statistical tests for
paired observations well adapted to the specificity of
radiotherapy where different data sets can be obtained
of the same patient. To compare two radiotherapy tech-
niques, the standard t-test can be used with parametric
data, whereas non-parametric Wilcoxon signed-rank test
should be used if the dose differences do not fulfill the
assumptions of parametric data. To compare several
techniques, the standard analysis of variance (ANOVA) can
be used with parametric data, whereas non-parametric
tests as the Friedman ANOVA should be used with non-
parametric data. Here we suggested statistical methods to
compare calculated doses in radiotherapy. These methods
can also be used to compare measured doses, e.g., using
two or more dosimeters, as well as to compare calculated
and measured doses.
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